Pharmaceutical Technology

JANUARY 17, 2023

Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The post Hospital Universitario and Josep Carreras develop cell therapy for leukaemia appeared first on Pharmaceutical Technology.

Hospitals 110

Hospitals Chemotherapy Communication Immunization 110

Pharmaceutical Technology

DECEMBER 8, 2022

In December last year, the first centre in Japan received authorisation to administer the therapy, while six regional hospitals are currently approved to offer this treatment. Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer.

Communication 122

Communication Immunization Hospitals 122

Pharmaceutical Technology

MAY 4, 2023

Of these three, the highest costs for US hospitals are from NTM i nfections at $1.53bn. Identifying the biggest risks for NTM infections in hospitals All healthcare facilities should have a water safety plan to control the opportunities and conditions to prevent bacteria growing and spreading. You can’t eradicate it completely.

Hospitals 52

Hospitals Documentation Communication Immunization 52

Pharmaceutical Technology

FEBRUARY 1, 2023

As paediatric hospital wings are flooded with an unprecedented number of respiratory syncytial virus (RSV) cases , healthcare workers have been overwhelmed by an unusually early peak of the RSV season. In the Northern hemisphere, RSV season occurs from autumn to the end of spring and tends to coincide with influenza season.

Vaccines 64

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 64

Pharmaceutical Technology

MARCH 21, 2023

Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease. BioCentriq is contracted to manufacture the biologic API.

Packaging 59

Packaging FDA Vaccines Communication 59

Pharmaceutical Technology

FEBRUARY 24, 2023

Since these adolescents are less likely to come to the hospital than babies and children, the focus needs to be on actively reaching out to those populations by using available platforms, such as school-based vaccinations. The primary target cohort is girls ages 9–14 years, which stands alone from other childhood vaccine services.

Vaccines 116

Vaccines Communication Medical Schools Immunization 116